Recent News

• 03.06.2025 - HeartBeam to Participate at Upcoming Conferences in Dana Point, California, March 16-21, 2025
• 02.27.2025 - HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time
• 02.25.2025 - HeartBeam Announces Exercise and Closing of Underwriter’s Over-Allotment Option for Public Offering of Common Stock
• 02.13.2025 - HeartBeam Announces Pricing of $10.0 Million Underwritten Public Offering of Common Stock
• 01.29.2025 - HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software
• 12.23.2024 - HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference
• 12.16.2024 - HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology
• 12.16.2024 - HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology
• 11.19.2024 - HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference
• 11.07.2024 - HeartBeam Reports Third Quarter 2024 Results

Recent Filings

• 02.26.2025 - 8-K Current report
• 02.26.2025 - EX-99.1 EX-99.1
• 02.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.18.2025 - EX-99.1 EX-99.1
• 02.18.2025 - 8-K Current report
• 02.14.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.08.2025 - FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
• 12.23.2024 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.07.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]